The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes
Open accessAbstract
BACKGROUND: Long-term trends in excess risk of death and cardiovascular outcomes have not been extensively studied in persons with type 1 diabetes or type 2 diabetes. METHODS: We included patients registered in the Swedish National Diabetes Register from 1998 through 2012 and followed them through 2014. Trends in deaths and cardiovascular events were estimated with Cox regression and standardized incidence rates. For each patient, controls who were matched for age, sex, and county were randomly selected from the general population. RESULTS: Among patients with type 1 diabetes, absolute changes during the study period in the incidence rates of sentinel outcomes per 10,000 person-years were as follows: death from any cause, -31.4 (95% confidence interval [CI], -56.1 to -6.7); death from cardiovascular disease, -26.0 (95% CI, -42.6 to -9.4); death from coronary heart disease, -21.7 (95% CI, -37.1 to -6.4); and hospitalization for cardiovascular disease, -45.7 (95% CI, -71.4 to -20.1). Absolute changes per 10,000 person-years among patients with type 2 diabetes were as follows: death from any cause, -69.6 (95% CI, -95.9 to -43.2); death from cardiovascular disease, -110.0 (95% CI, -128.9 to -91.1); death from coronary heart disease, -91.9 (95% CI, -108.9 to -75.0); and hospitalization for cardiovascular disease, -203.6 (95% CI, -230.9 to -176.3). Patients with type 1 diabetes had roughly 40% greater reduction in cardiovascular outcomes than controls, and patients with type 2 diabetes had roughly 20% greater reduction than controls. Reductions in fatal outcomes were similar in patients with type 1 diabetes and controls, whereas patients with type 2 diabetes had smaller reductions in fatal outcomes than controls. CONCLUSIONS: In Sweden from 1998 through 2014, mortality and the incidence of cardiovascular outcomes declined substantially among persons with diabetes, although fatal outcomes declined less among those with type 2 diabetes than among controls. (Funded by the Swedish Association of Local Authorities and Regions and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Atherosclerotic cardiovascular disease (ASCVD) broadly refers to a history of acute coronary syndrome, myocardial infarction (MI), stable or unstable angina or coronary or other arterial revascularization, stroke, transient ischemic attack, or peripheral artery disease (PAD) including aortic aneurysm and is the leading cause of morbidity and mortality in people with diabetes (1).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“ASCVD broadly refers to a history of acute coronary syndrome, myocardial infarction (MI), stable or unstable angina or coronary or other arterial revascularization, stroke, or peripheral artery disease (PAD) including aortic aneurysm and is the leading cause of morbidity and mortality in people with diabetes (1).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [1]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Under the current paradigm of comprehensive risk factor modification, cardiovascular morbidity and mortality have notably decreased in people with both type 1 and type 2 diabetes (1).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“Under the current paradigm of comprehensive risk factor modification, cardiovascular morbidity and mortality have notably decreased in people with both type 1 and type 2 diabetes (1).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [1]
In the citing paper
“T2DM is common among patients with ASCVD or at the highest risk of CVD.The converse is also true: ASCVD is common in patients with T2DM.148”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [148]
In the citing paper
“Diabetes is a well-established risk factor for ischaemic heart disease (IHD), and CAD accounts for 40-80% of deaths in patients with T2DM.148,359,381”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [148]
In the citing paper
“These results were consistent across subgroups including those with and without diabetes or CKD.”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [50]
In the citing paper
“The primary outcome of worsening HF or CVD death was significantly reduced, 16.3% versus 21.2% for dapagliflozin compared with placebo (HR, 0.74; 95% CI, 0.65–0.85).”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [50]
In the citing paper
“Patients with T2DM are at high risk for ASCVD and HF compared with nondiabetic individuals (50,53).”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [50]
In the citing paper
“DAPA-HF was the first clinical trial of an SGLT2 inhibitor to assess HF events as the primary outcome and to include participants with and without diabetes (50).”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [50]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
C-Reactive Protein, Interleukin 6, and Risk of Developing Type 2 Diabetes Mellitus
Pradhan, A. D. (2001) · JAMA · doi:10.1001/jama.286.3.327 · Cited by 4,433
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378
IDF Diabetes Atlas: Global estimates of the prevalence of diabetes for 2011 and 2030
Whiting, D. R., Guariguata, L., Weil, C., & Shaw, J. E. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2011.10.029 · Cited by 4,018
Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755
Effect of a multifactorial intervention on mortality in type 2 diabetes
Gæde, P., Lund-Andersen, H., Parving, H.-H., & Pedersen, O. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706245 · Cited by 3,465
Flagged first, then by citations
Cited by
Sorted by citations
Items 801–900 of 1,000
Diabetes mellitus im Kindes- und Jugendalter (Update 2023)
Rami-Merhar, B. M., Fröhlich-Reiterer, E. E., Hofer, S. E., & Fritsch, M. (2023) · Wiener klinische Wochenschrift · doi:10.1007/s00508-023-02169-5 · Cited by 5
Wong, P. S., Tong, C. V., Bidin, M. B. L., & Adam, N. L. (2023) · The Journal of the Royal College of Physicians of Edinburgh · doi:10.1177/14782715231170958 · Cited by 5
Popovic, D. S., Koufakis, T., Patoulias, D., & Παπάνας, Ν. (2023) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2023.2274988 · Cited by 5
Perea, V., Vinagre, I., Serés‐Noriega, T., Viñals, C., Mesa, A., Pané, A., Milad, C., Esmatjes, E., Conget, I., Giménez, M., et al. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad755 · Cited by 5
Wörmeyer, L., Nortmann, O., Hamacher, A. B., Uhlemeyer, C., Belgardt, B., Eberhard, D., Mayatepek, E., Meißner, T., Lammert, E., & Welters, A. (2024) · Hormone and Metabolic Research · doi:10.1055/a-2236-8625 · Cited by 5
Avdic, T., Eliasson, B., Rawshani, A., Borén, J., Gerstein, H. C., Nordanstig, J., Rihawi, M., Beckman, J. A., McGuire, D. K., Ömerovic, E., et al. (2024) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2024.100852 · Cited by 6
Self-citationAlfadhly, A. F., Mohammed, A., Almalki, B. T., Alfaez, S. M., Mubarak, A. S., Alotaibi, E. A., Al-Omran, G. H., Almathami, J., Bazhair, N., AlShamrani, N. A., et al. (2024) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_1661_23 · Cited by 5
Kamiński, M., Kulecki, M., Kasprzak, D., Lachowski, P., Kulczycka, A., Kozłowska, M., Klause, D., Naskręt, D., Flotyńska, J., Zozulińska‐Ziółkiewicz, D., et al. (2025) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2025.103853 · Cited by 5
Khunti, K., Seidu, S., & Davies, M. J. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13518 · Cited by 5
Practical use of electronic health records among patients with diabetes in scientific research
Shen, Y., Zhou, J., & Hu, G. (2020) · Chinese Medical Journal · doi:10.1097/cm9.0000000000000784 · Cited by 5
Persson, S., Nilsson, K., Karlsdotter, K., Skogsberg, J., Gustavsson, S., JENDLE, J. H., & Carlsson, K. S. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14919 · Cited by 5
Alam, N. N., Wright, A. K., Rutter, M. K., Buchan, I. E., Ashcroft, D. M., Sperrin, M., & Renehan, A. G. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14614 · Cited by 5
Ameliorating Cardiovascular Risk in Patients with Type 2 Diabetes
Motairek, I. K., & Al-Kindi, S. G. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2022.07.002 · Cited by 5
Chen, T., Wang, Z., Xie, J., Xiao, S., & Liu, N. (2023) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2023.04.012 · Cited by 5
Diabetestechnologie (Update 2023)
Schütz-Fuhrmann, I., Rami-Merhar, B. M., Fröhlich-Reiterer, E. E., Hofer, S. E., Tauschmann, M., Mader, J. K., Resl, M., Kautzky‐Willer, A., Winhofer-Stöckl, Y., Laimer, M., et al. (2023) · Wiener klinische Wochenschrift · doi:10.1007/s00508-023-02165-9 · Cited by 5
Beyond Statins: Who and When to Prescribe?
Ganda, O. P. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1087-0 · Cited by 5
Napoli, R., Fanelli, F., Gazzi, L., Larosa, M., Bitonti, R., & Furneri, G. (2020) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2020.07.005 · Cited by 5
Exciting breakthroughs in the management of diabetes mellitus
Scheen, A. J. (2021) · Diabetes Epidemiology and Management · doi:10.1016/j.deman.2021.100005 · Cited by 6
Wang, L., Xiang, L., Piao, S., Gong, X., Zhou, W.-X., Feng, W., Li, H.-L., Li, L., Wei, A., Zhu, Q., et al. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s309419 · Cited by 5
Fagbamigbe, A. F., Norrman, E., Bergh, C., Wennerholm, U., & Petzold, M. (2021) · PLoS ONE · doi:10.1371/journal.pone.0253389 · Cited by 5
Nørgaard, C. H., Starkopf, L., Gerds, T. A., Malmborg, M. W., Bonde, A. N., Zareini, B., Mills, E. H. A., Vestergaard, P., Wong, N. D., Torp-Pedersen, C. T., et al. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2022.108126 · Cited by 5
Cosson, E., Berkane, N., Pinto, S., Bihan, H., Tatulashvili, S., Soussan, M., Sellier, N., Nguyen, M. T., & Valensi, P. E. (2022) · Diabetes & Metabolism · doi:10.1016/j.diabet.2022.101412 · Cited by 5
Editorial: Heart Failure in Type 2 Diabetes – The “Forgotten” Complication
Guja, C., & Miulescu, R. D. (2018) · Romanian Journal of Diabetes Nutrition and Metabolic Diseases · doi:10.2478/rjdnmd-2018-0014 · Cited by 5
Mähs, M., Pithan, J. S., Bergmann, I., Gabrys, L., Graf, J., Hölzemann, A., Van Laerhoven, K., Otto-Hagemann, S., Popescu, M. L., Schwermann, L., et al. (2022) · Trials · doi:10.1186/s13063-022-06550-z · Cited by 4
Liu, Y. Y., Wang, P., Wang, M., Chen, Y., Kasyanju, S. M., Yang, Y., Yang, T., Peng, L., & Sun, M. (2025) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s558687 · Cited by 4
Cardiovascular outcome trials in type 2 diabetes: A nurse practitioner perspective
Kruger, D. F. (2018) · Journal of the American Association of Nurse Practitioners · doi:10.1097/jxx.0000000000000126 · Cited by 4
Varkevisser, R. D. M., Mul, D., Aanstoot, H., Wolffenbuttel, B. H. R., & van der Klauw, M. M. (2023) · BMJ Open · doi:10.1136/bmjopen-2023-073690 · Cited by 4
Claessen, H., Narres, M., Heier, M., Kvitkina, T., Linkohr, B., Wolff, G., Roden, M., Icks, A., & Peters, A. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02179-1 · Cited by 4
Trends in Survival After First Myocardial Infarction in People With Diabetes
Glynn, L., Lind, M., Andersson, T., Eliasson, B., Hofmann, R., & Nyström, T. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.034741 · Cited by 4
Self-citationSarabhai, T., & Kostev, K. (2025) · Journal of Diabetes · doi:10.1111/1753-0407.70099 · Cited by 4
Targeting cardiometabolic risk in type 1 diabetes through incretin physiology
Frampton, R., HOCKING, S. L., SNAITH, J. R., & Greenfield, J. R. (2025) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2025.06.004 · Cited by 4
Basak, M., Dey, S. K., Ghosh, S., Bhattacharjee, D., Nayek, A., & Jana, A. (2025) · Indian Journal of Pathology and Microbiology · doi:10.4103/ijpm.ijpm_99_25 · Cited by 4
Ezzatvar, Y., López‐Gil, J. F., Sepulveda, R. A. Y., Almonacid, J. G. H., & García‐Hermoso, A. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1704277 · Cited by 4
Coronary Stent Failure in Patients With Diabetes: A Nationwide Observational Study From SWEDEHEART
Santos‐Pardo, I., Andersson, M., Hofmann, R., & Nyström, T. (2025) · Diabetes Care · doi:10.2337/dc25-1624 · Cited by 4
Abel, E. D., Ahima, R. S., Anderson, E. J., Berg, D. D., Berger, J. S., Das, S., Feinberg, M. W., Fisher, E. A. A., Garshick, M. S., Giannarelli, C., et al. (2026) · Circulation Research · doi:10.1161/circresaha.125.325798 · Cited by 4
Mertens, J., Stoop, T., Dirinck, E. L., Francque, S., Heuten, H., & Block, C. E. M. D. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03114-2 · Cited by 4
From survival to freedom: redefining success in type 1 diabetes
Piemonti, L. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00003-3 · Cited by 4
Transatlantic guidelines on dyslipidemia and cardiovascular risk: key differences across the pond
Agha, A. M., Virani, S. S., & Ballantyne, C. M. (2020) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000608 · Cited by 4
Berg, D. D., Kolkailah, A. A., Sarraju, A., Kerchberger, A. M., Eljalby, M., & McGuire, D. K. (2021) · Current Diabetes Reports · doi:10.1007/s11892-021-01417-0 · Cited by 4
Self-citationRohde, C., Thomsen, R. W., & Østergaard, S. D. (2022) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001508 · Cited by 4
Gut immune cells—A novel therapeutical target for cardiovascular disease?
Ganesh, N., van der Vorst, E. P. C., Spießhöfer, J., He, S., Burgmaier, M., Findeisen, H. M., Lehrke, M., Świrski, F. K., Marx, N., & Kahles, F. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.943214 · Cited by 4
Small steps forward: Adjunctive therapy for T1D
Bloomgarden, Z. T., & Schatz, D. (2022) · Journal of Diabetes · doi:10.1111/1753-0407.13326 · Cited by 4
Nano Architect-Based Targeted Delivery Systems for Diabetic Nephropathy: A Review
Rawat, A., Jhawat, V., & Dutt, R. (2023) · Current Drug Targets · doi:10.2174/1389450124666230601163338 · Cited by 4
Effects of COVID-19 on diabetes care among dutch diabetes outpatients
Bak, J. C. G., Serné, E. H., Groenwold, R. H. H., de Valk, H. W., Kramer, M. H. H., Nieuwdorp, M., & Verheugt, C. L. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01169-9 · Cited by 4
Sinha, T., Gul, U., Babar, N. N., Israr, F., Butt, A. A., Chaudhari, S. S., Maqbool, H., & Amin, A. (2024) · Cureus · doi:10.7759/cureus.69711 · Cited by 4
HADDAD, J. A., Annabi, F. A., Abbasi, H., Al-Samen, M. A. A., Ammari, F. L., Haddad, F., Haddad, S. E., Jaradat, M., Khassawneh, A., Khatib, N., et al. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01718-7 · Cited by 4
Batista, J. L., Makuvire, T. T., Davis, J. D., & Carbone, S. (2025) · US Cardiology Review · doi:10.15420/usc.2024.44 · Cited by 4
Shestakova, M. V., Kharakhulakh, M. I., & Belolipetsky, Y. A. (2025) · Diabetes Mellitus · doi:10.14341/dm13238 · Cited by 4
Cardiovascular benefits of metformin in T1DM
Snell‐Bergeon, J. K. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.116 · Cited by 4
Patoulias, D., Papadopoulos, C. E., Kalogirou, M., Katsimardou, A., Toumpourleka, M., & Doumas, M. N. (2020) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2020.10.001 · Cited by 4
Kubota, M., Shiroyama, E., Tanaka, K., & Yoshii, Y. (2021) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-020-00707-0 · Cited by 4
Hitchen, S. A., Lan, N. S. R., Hort, A. L., Rankin, J. M., Fegan, P. G., & Yeap, B. B. (2021) · Internal Medicine Journal · doi:10.1111/imj.15245 · Cited by 4
Harding, J. L., Benoit, S. R., HORA, I. A., Sridharan, L., Ali, M. K., Jagannathan, R., Patzer, R. E., & Narayan, K. M. V. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002377 · Cited by 4
Lithovius, R., Antikainen, A. A., Mutter, S., Valo, E., Forsblom, C. M., Harjutsalo, V., Sandholm, N., & Groop, P. (2022) · Diabetes Care · doi:10.2337/dc21-0974 · Cited by 5
Treatment of diabetes mellitus has borne much fruit in the prevention of cardiovascular disease
Yagyu, H., & Shimano, H. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13859 · Cited by 4
EVOO’s Effects on Incretin Production: Is There a Rationale for a Combination in T2DM Therapy?
Amodeo, S., Mirarchi, L., Seidita, A., Citarrella, R., Licata, A., Soresi, M., Iovanna, J., & Giannitrapani, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231710120 · Cited by 5
Valensi, P. E., Berkane, N., Pinto, S., Sellier, N., Soussan, M., Nguyen, M. T., & Cosson, E. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01760-4 · Cited by 5
RETRACTED: Non-neuronal cholinergic system delays cardiac remodelling in type 1 diabetes
Munasinghe, P. E., Saw, E. L., Reily-Bell, M., Tonkin, D., Kakinuma, Y., Fronius, M., & Katare, R. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e17434 · Cited by 7
RetractedDejby, E., Bhatt, D. L., Skoglund, K., Rawshani, A., Ömerovic, E., Redfors, B., Myredal, A., Pétursson, P., Angerås, O., Gustafsson, A., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-39570-z · Cited by 4
Self-citationThe role of captopril in leukotriene deficient type 1 diabetic mice
Guimarães, J. P. T., Queiroz, L. A. D., Menikdiwela, K. R., Pereira, N., Ramalho, T. R. D. O., Jancar, S., Moustaïd‐Moussa, N., & Martins, J. O. (2023) · Scientific Reports · doi:10.1038/s41598-023-49449-8 · Cited by 4
Xue, Z.-K., Dai, X., Ren, J., Liu, T., Zhang, Y., Hu, S., Wang, P., Wu, X., Zhang, J., Tse, G., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-65426-1 · Cited by 4
Sleep Disturbances in Type 1 Diabetes and Mitigating Cardiovascular Risk
Irsheed, G. A., Martyn-Nemeth, P. A., Baron, K. G., & Reutrakul, S. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae539 · Cited by 4
Reed, S. D., Li, Y., Leal, J., Radican, L., Adler, A., Alfredsson, J., Buse, J. B., Green, J. B., Kaufman, K. D., Riefflin, A., et al. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13292 · Cited by 4
Die Behandlung des Diabetes mellitus: Mythen und Evidenz
Göke, B. (2020) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/s00103-020-03124-9 · Cited by 4
Hoosen, M. Z., Paruk, I. M., Pirie, F. J., & Motala, A. A. (2020) · Journal of Endocrinology Metabolism and Diabetes of South Africa · doi:10.1080/16089677.2020.1748321 · Cited by 4
Diabetes mellitus can cause cardiomyopathy disorders by inducing the aging pathway.
Ahmadi, M., Saberianpour, S., Heidarzadeh, M., & Rezaie, J. (2021) · PubMed Central · doi:10.22038/ijbms.2021.54783.12287 · Cited by 4
Chen, H.-H., Wu, C., Tsai, Y., Ho, C.-W., Hsieh, M., & Lai, J. (2021) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2021/1298487 · Cited by 4
Zhang, X., Wu, H., Lau, E. S. H., Fan, B., Tsoi, K. Y., Tam, C. H. T., Yang, A., Shi, M., Chow, E., Kong, A. P. S., et al. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14167 · Cited by 4
Martins, N. S., Mello, D. S. S., Barreto, J., Soares, A., Breder, I. S. S., Cunha, J. S., Nadruz, W., Coelho‐Filho, O. R., Matos‐Souza, J. R., Coelho, O. R., et al. (2019) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.65.1.3 · Cited by 4
Haslacher, H., Fallmann, H., Waldhäusl, C., Hartmann, E., Wagner, O. F., & Waldhäusl, W. K. (2019) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s197495 · Cited by 4
Alzheimer’s Disease and Type 2 Diabetes Mellitus: Molecular Mechanisms and Similarities
León, K. I. L.-D., Bertadillo-Jilote, A. D., García-Gutiérrez, D. G., & Meraz‐Ríos, M. A. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.92581 · Cited by 4
Koskinas, K. C., Melmer, A., Steiner, N., Gübeli, A., Wilhelm, M., & Laimer, M. W. (2021) · Praxis · doi:10.1024/1661-8157/a003589 · Cited by 4
Pujante, P., Torre, E. L. M., Morales-Sánchez, P., Escobedo, R. R., Barreiro, S. C., Rojo‐Martínez, G., & Delgado, E. (2022) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2020.12.040 · Cited by 4
Zaman, N., Dar, M. H., Adnan, Y., Noor, L., Naz, G., & ., Z. (2018) · Pakistan Journal of Medical Sciences · doi:10.12669/pjms.342.13848 · Cited by 4
Popovic, D. S., Koufakis, T., & Παπάνας, Ν. (2023) · Current Vascular Pharmacology · doi:10.2174/1570161121666230817105105 · Cited by 4
Mortality for type 2 diabetes mellitus in the state of São Paulo, Brazil, from 2008 to 2017
dos Santos, A., Paiva, L. D. S., Carvalho, L. E. W. D., Fonseca, F. L. A., do Nascimento, V. B., Corrêa, J. A., Ribeiro, M. A. L., Bezerra, Í. M. P., de Abreu, L. C., & Adami, F. (2022) · Diabetes Epidemiology and Management · doi:10.1016/j.deman.2022.100067 · Cited by 3
Lamacchia, O., Menzaghi, C., Copetti, M., Mastroianno, M., Corsano, C., Prehn, C. P., Adamski, J., Fontana, A., Trischitta, V., & Cosmo, S. D. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae551 · Cited by 3
Tatulashvili, S., Dreves, B., Cosson, E., Meyer, L., Morello, R., & Joubert, M. (2025) · PLoS ONE · doi:10.1371/journal.pone.0318746 · Cited by 3
Park, Y. S., Lee, K., Koo, B. K., Kwak, S. H., Han, K., & Moon, M. K. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112373 · Cited by 3
Bebe, A. C. K. M., Willadsen, T. G., Kragstrup, J., Nielsen, A. B. S., Møller, A. M., Søndergaard, J., Siersma, V., Nicolaisdóttir, D. R., Hølmkjær, P., & Waldorff, F. B. (2025) · BMC Geriatrics · doi:10.1186/s12877-025-06319-4 · Cited by 3
Martino, N. D., Angelino, S., Maio, A., Cirillo, P., Pontillo, A., Caputo, M., Scappaticcio, L., Caruso, P., Longo, M., Bellastella, G., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26189196 · Cited by 3
Kwon, O. C., Ha, J. W., Park, M., Park, Y., & Lee, S. (2025) · Revista Brasileira de Reumatologia · doi:10.1186/s42358-025-00476-1 · Cited by 3
Averta, C., Rubino, M., Mancuso, E., Massimino, M., Coppolino, G., Bolignano, D., Cassano, V., Greco, M., Palummo, A., Sciacqua, A., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07079-w · Cited by 3
Al‐Senani, G. M., Al‐Qahtani, S. D., Mahgoub, S. M., Ahmed, H. A., & Mohamed, M. A. (2025) · Reviews in Analytical Chemistry · doi:10.1515/revac-2025-0091 · Cited by 3
Kar, D., Molokhia, M., Wierzbicki, A. S., Koziell, A. B., Byng, R., Spicer, S. G., Farina, N., Pinkney, J. H., Song, S. H., Zabeen, B., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-24521-7 · Cited by 3
Hu, T., Zhang, W., Ding, X., Han, F., & An, Z. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02981-5 · Cited by 3
Lyu, L., Kao, C., Su, J., Yu, Y., Zhang, X., Lyu, J., Che, J., & Zhang, J. (2026) · Lipids in Health and Disease · doi:10.1186/s12944-025-02852-8 · Cited by 4
Cornelio, C. K., Cowart, K., Perkins, J. B., Alomar, M., Pineda-Gayoso, R., Miranda, A. C., Phan, A. T., & White, R. T. (2026) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.70130 · Cited by 3
Baldissera, S., Minardi, V., Masocco, M., & Ferrante, G. (2022) · European Journal of Public Health · doi:10.1093/eurpub/ckac037 · Cited by 3
Wang, X., Zhou, Y., Huang, Z., Yu, X., Chen, Z., Cai, Z., Lan, Y., Li, W., Cai, Z., Fang, W., et al. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.882984 · Cited by 3
Coronary artery disease patients with rs7904519 (TCF7L2) are at a persistent risk of type 2 diabetes
Hageh, C. A., O’Sullivan, S., Platt, D. E., Henschel, A., Chacar, S., Gauguier, D., Abchee, A., Alefishat, E. A., Nader, M., & Zalloua, P. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.111052 · Cited by 3
Zhang, A., Kalil, R. K., Marzec, A., Coulter, S., Virani, S. S., Patel, K. V., & Segar, M. W. (2024) · Texas Heart Institute Journal · doi:10.14503/thij-23-8375 · Cited by 4
Wang, W., Han, R., Lai, L., & Zhang, X. (2024) · Molecular & Cellular Toxicology · doi:10.1007/s13273-024-00434-w · Cited by 3
Machine Learning-Based Diabetes Risk Prediction Using Associated Behavioral Features
Ibitoye, A., Akinyemi, J. D., & Onifade, O. F. W. (2024) · Computing Open · doi:10.1142/s2972370124500065 · Cited by 3
Sattler, E. L. P., Lassale, C. M., Diaw, M., Joseph, J. J., Singh, G., Samb, A., Lloyd‐Jones, D. M., & Gaye, B. (2024) · JACC Advances · doi:10.1016/j.jacadv.2024.101450 · Cited by 3
Causes of Death After Coronary Revascularization in Patients With Diabetes
Godoy, L. C., Fuster, V., Razzouk, L., Dangas, G., Sethi, S. S., Sidhu, M. S., Rodríguez, A. E., Solomon, S. D., & Farkouh, M. E. (2024) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2024.12.013 · Cited by 3
Schmitt, V. H., Hobohm, L., Hahad, O., Sivanathan, V., Schmidt, F. P., Münzel, T. F., Lurz, P. C., Gori, T., & Keller, K. (2025) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2025.103201 · Cited by 3
Gao, D., & Wang, A. (2025) · BMC Cardiovascular Disorders · doi:10.1186/s12872-025-04742-4 · Cited by 3
Lee, D. Y., Moon, S. J., Han, K., Ko, J.-H., Jang, H.-N., Kwon, H. M., Park, S.-E., Rhee, E., & Lee, W. (2025) · Endocrinology and Metabolism · doi:10.3803/enm.2024.2275 · Cited by 3
Husdal, R., Adolfsson, E. T., Leksell, J. K., Eliasson, B., Jansson, S. P. O., Jerdén, L., Stålhammar, J., Steen, L., Wallman, T., Svensson, A., et al. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108352 · Cited by 3
Self-citation
Metadata
- Authors
- Rawshani, A., Rawshani, A., Franzén, S., Eliasson, B., Svensson, A.-M., Miftaraj, M., McGuire, D. K., Sattar, N., Rosengren, A., & Gudbjörnsdottir, S.
- Affiliations
- University of Glasgow (GB)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-04-13
- Volume
- 376
- Issue
- 15
- Pages
- 1407-1418
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2606281213
- Cited by
- 1,389
- References
- 37
- Citations by year
- 2026: 100 · 2025: 144 · 2024: 163 · 2023: 149 · 2022: 184 · 2021: 176 · 2020: 196 · 2019: 140 · 2018: 95 · 2017: 39
- FWCI
- 101.54
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- type 1 diabetes, type 2 diabetes, cardiovascular disease, mortality, coronary artery disease, cardiovascular hospitalization, Sweden, diabetes registry, standardized incidence rate
- MeSH terms
- Adolescent, Adult, Aged, Cardiovascular Diseases, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Female, Hospitalization, Humans, Male, Middle Aged, Mortality, Registries, Risk Factors, Sweden, Incidence, Proportional Hazards Models, Age of Onset
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
